- Data Presentation at 48th ICAAC / IDSA 46th Annual Meeting -
PRINCETON, N.J. and ANNAPOLIS, Md., Oct. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX), a leading monoclonal antibody company, and PharmAthene, Inc. (NYSE: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a pilot study showing that the anthrax anti-toxin, Valortim(R) (MDX-1303), enhanced survival as compared to a control group in a therapeutic animal model known as the New Zealand White (NZW) rabbit model. Valortim is a fully human monoclonal antibody generated by Medarex's UltiMAb(R) technology that is being co-developed by the two companies for potential use as an anti- toxin therapeutic to prevent and treat inhalation anthrax.
The data were presented in an oral presentation entitled "Therapeutic Efficacy of MDX-1303, an Anti-toxin Monoclonal Antibody, for Inhalation Anthrax in the New Zealand White (NZW) Rabbit Model" at the 48th ICAAC/ IDSA 46th Annual Meeting by Israel Lowy, M.D., Ph.D., Senior Director of Clinical Science and Infectious Diseases at Medarex.
David P. Wright, President & Chief Executive Officer of PharmAthene,
commented, "Mounting evidence from a number of animal studies suggests that
Valortim may be efficacious as both a prophylactic and therapeutic for
inhalation anthrax infection. Based on these results, we believe that
Valortim is ideally positioned for procurement consideration in the
Strategic National Stockpile,
|SOURCE Medarex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved